A citation-based method for searching scientific literature

Amreen Husain, Yan Wang, Lars C Hanker, Belén Ojeda, Maarit Anttila, Enrico Breda, Peter Vuylsteke, Eric Pujade-Lauraine. Gynecol Oncol 2016
Times Cited: 12







List of co-cited articles
35 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Eric Pujade-Lauraine, Felix Hilpert, Béatrice Weber, Alexander Reuss, Andres Poveda, Gunnar Kristensen, Roberto Sorio, Ignace Vergote, Petronella Witteveen, Aristotelis Bamias,[...]. J Clin Oncol 2014
766
75

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Carol Aghajanian, Stephanie V Blank, Barbara A Goff, Patricia L Judson, Michael G Teneriello, Amreen Husain, Mika A Sovak, Jing Yi, Lawrence R Nycum. J Clin Oncol 2012
781
50



Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial.
Anne Floquet, Ignace Vergote, Nicoletta Colombo, Bent Fiane, Bradley J Monk, Alexander Reinthaller, Paula Calvert, Thomas J Herzog, Werner Meier, Jae-Weon Kim,[...]. Gynecol Oncol 2015
20
33

Independent radiologic review: bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer.
Carol Aghajanian, Barbara Goff, Lawrence R Nycum, Yan Wang, Amreen Husain, Stephanie Blank. Gynecol Oncol 2014
20
33

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.
Bradley J Monk, Thomas J Herzog, Stanley B Kaye, Carolyn N Krasner, Jan B Vermorken, Franco M Muggia, Eric Pujade-Lauraine, Alla S Lisyanskaya, Anatoly N Makhson, Janusz Rolski,[...]. J Clin Oncol 2010
267
25

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
Joyce F Liu, William T Barry, Michael Birrer, Jung-Min Lee, Ronald J Buckanovich, Gini F Fleming, Bj Rimel, Mary K Buss, Sreenivasa Nattam, Jean Hurteau,[...]. Lancet Oncol 2014
356
25

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.
Jonathan A Ledermann, Andrew C Embleton, Fharat Raja, Timothy J Perren, Gordon C Jayson, Gordon J S Rustin, Stan B Kaye, Hal Hirte, Elizabeth Eisenhauer, Michelle Vaughan,[...]. Lancet 2016
129
25

Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE).
Christian Kurzeder, Isabel Bover, Frederik Marmé, Joern Rau, Patricia Pautier, Nicoletta Colombo, Domenica Lorusso, Petronella Ottevanger, Maria Bjurberg, Christian Marth,[...]. J Clin Oncol 2016
38
25

Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Robert A Burger, Mark F Brady, Michael A Bookman, Gini F Fleming, Bradley J Monk, Helen Huang, Robert S Mannel, Howard D Homesley, Jeffrey Fowler, Benjamin E Greer,[...]. N Engl J Med 2011
25

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
25

Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers.
Jovana Y Martin, Renata R Urban, John B Liao, Barbara A Goff. J Gynecol Oncol 2016
9
22

Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.
Robert L Coleman, James Moon, Anil K Sood, Wei Hu, James E Delmore, Albert J Bonebrake, Garnet L Anderson, Setsuko K Chambers, Maurie Markman. Eur J Cancer 2014
19
16

2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference.
Gavin C E Stuart, Henry Kitchener, Monica Bacon, Andreas duBois, Michael Friedlander, Jonathan Ledermann, Christian Marth, Tate Thigpen, Edward Trimble. Int J Gynecol Cancer 2011
273
16

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.
Bradley J Monk, Andrés Poveda, Ignace Vergote, Francesco Raspagliesi, Keiichi Fujiwara, Duk-Soo Bae, Ana Oaknin, Isabelle Ray-Coquard, Diane M Provencher, Beth Y Karlan,[...]. Lancet Oncol 2014
187
16

Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. N Engl J Med 2012
16

Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.
Sandro Pignata, Domenica Lorusso, Giovanni Scambia, Daniela Sambataro, Stefano Tamberi, Saverio Cinieri, Anna M Mosconi, Michele Orditura, Alba A Brandes, Valentina Arcangeli,[...]. Lancet Oncol 2015
86
16

PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.
R Wendel Naumann, Robert L Coleman, Robert A Burger, Edward A Sausville, Elzbieta Kutarska, Sharad A Ghamande, Nashat Y Gabrail, Stephen E Depasquale, Elzbieta Nowara, Lucy Gilbert,[...]. J Clin Oncol 2013
132
16

Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
Eric Pujade-Lauraine, Uwe Wagner, Elisabeth Aavall-Lundqvist, Val Gebski, Mark Heywood, Paul A Vasey, Birgit Volgger, Ignace Vergote, Sandro Pignata, Annamaria Ferrero,[...]. J Clin Oncol 2010
342
16

Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
Nicoletta Colombo, Elzbieta Kutarska, Meletios Dimopoulos, Duk-Soo Bae, Izabella Rzepka-Gorska, Mariusz Bidzinski, Giovanni Scambia, Svend Aage Engelholm, Florence Joly, Dirk Weber,[...]. J Clin Oncol 2012
84
16

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Mansoor R Mirza, Bradley J Monk, Jørn Herrstedt, Amit M Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A Ledermann, Domenica Lorusso, Ignace Vergote,[...]. N Engl J Med 2016
16


Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer.
Martin R Stockler, Felix Hilpert, Michael Friedlander, Madeleine T King, Lari Wenzel, Chee Khoon Lee, Florence Joly, Nikolaus de Gregorio, José Angel Arranz, Mansoor Raza Mirza,[...]. J Clin Oncol 2014
110
16

Recommendations for the assessment of progression in randomised cancer treatment trials.
J E Dancey, L E Dodd, R Ford, R Kaplan, M Mooney, L Rubinstein, L H Schwartz, L Shankar, P Therasse. Eur J Cancer 2009
74
16

Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?
Lori E Dodd, Edward L Korn, Boris Freidlin, C Carl Jaffe, Lawrence V Rubinstein, Janet Dancey, Margaret M Mooney. J Clin Oncol 2008
115
16

Lessons learned from independent central review.
R Ford, L Schwartz, J Dancey, L E Dodd, E A Eisenhauer, S Gwyther, L Rubinstein, D Sargent, L Shankar, P Therasse,[...]. Eur J Cancer 2009
70
16


Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.
Noriyuki Katsumata, Makoto Yasuda, Fumiaki Takahashi, Seiji Isonishi, Toshiko Jobo, Daisuke Aoki, Hiroshi Tsuda, Toru Sugiyama, Shoji Kodama, Eizo Kimura,[...]. Lancet 2009
486
16

Ovarian cancer statistics, 2018.
Lindsey A Torre, Britton Trabert, Carol E DeSantis, Kimberly D Miller, Goli Samimi, Carolyn D Runowicz, Mia M Gaudet, Ahmedin Jemal, Rebecca L Siegel. CA Cancer J Clin 2018
957
16

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
Andreas du Bois, Gunnar Kristensen, Isabelle Ray-Coquard, Alexander Reuss, Sandro Pignata, Nicoletta Colombo, Ursula Denison, Ignace Vergote, Jose M Del Campo, Petronella Ottevanger,[...]. Lancet Oncol 2016
126
16

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke,[...]. N Engl J Med 2018
775
16

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.
Robert A Burger, Michael W Sill, Bradley J Monk, Benjamin E Greer, Joel I Sorosky. J Clin Oncol 2007
569
16

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
Jaafar Bennouna, Javier Sastre, Dirk Arnold, Pia Österlund, Richard Greil, Eric Van Cutsem, Roger von Moos, Jose Maria Viéitez, Olivier Bouché, Christophe Borg,[...]. Lancet Oncol 2013
720
16

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.
Ignace Vergote, Claes G Tropé, Frédéric Amant, Gunnar B Kristensen, Tom Ehlen, Nick Johnson, René H M Verheijen, Maria E L van der Burg, Angel J Lacave, Pierluigi Benedetti Panici,[...]. N Engl J Med 2010
16

Gastrointestinal perforation during regorafenib administration in a case with hepatic metastases of colon cancer.
Kenichi Ogata, Hiroshi Takamori, Naoki Umezaki, Taisuke Yagi, Katsuhiro Ogawa, Nobuyuki Ozaki, Hiromitsu Hayashi, Hideyuki Tanaka, Yoshiaki Ikuta, Koichi Doi. J Chemother 2017
4
25

Lymphangiogenesis in Crohn's disease: an immunohistochemical study using monoclonal antibody D2-40.
F Pedica, C Ligorio, P Tonelli, S Bartolini, P Baccarini. Virchows Arch 2008
61
8

Bevacizumab can induce reactivity to VEGF-C and -D in human brain and tumour derived endothelial cells.
S Grau, J Thorsteinsdottir, L von Baumgarten, F Winkler, J-C Tonn, C Schichor. J Neurooncol 2011
22
8

Experimental regional enteritis in pigs.
T V Kalima, H Saloniemi, T Rahko. Scand J Gastroenterol 1976
43
8

Cooperative and redundant roles of VEGFR-2 and VEGFR-3 signaling in adult lymphangiogenesis.
Jeremy Goldman, Joseph M Rutkowski, Jacqueline D Shields, Miriella C Pasquier, Yingjie Cui, Hugo G Schmökel, Stephen Willey, Daniel J Hicklin, Bronislaw Pytowski, Melody A Swartz. FASEB J 2007
110
8

Antiangiogenic therapies in ovarian cancer.
Alexander Reinthaller. Memo 2016
15
8

Role of the lymphatic system in the pathogenesis of Crohn's disease.
Pierre-Yves von der Weid, Sonia Rehal, José Gp Ferraz. Curr Opin Gastroenterol 2011
75
8



Microanatomy of the intestinal lymphatic system.
Mark J Miller, Jeremiah R McDole, Rodney D Newberry. Ann N Y Acad Sci 2010
41
8

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer.
Jonathan A Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. Br J Cancer 2016
36
8

A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer.
G Rustin, N Reed, G C Jayson, J A Ledermann, M Adams, T Perren, C Poole, M Lind, M Persic, S Essapen,[...]. Ann Oncol 2011
22
8

A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer.
Angeles Alvarez Secord, Andrew Berchuck, Robert V Higgins, Lawrence R Nycum, Matthew F Kohler, Larry E Puls, Robert W Holloway, George S Lewandowski, Fidel A Valea, Laura J Havrilesky. Cancer 2012
6
16

Cancer of the ovary.
Stephen A Cannistra. N Engl J Med 2004
8



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.